Who is sponsoring NCT04094038?

NCT04094038 is sponsored by Erasmus Medical Center.

What condition does NCT04094038 study?

NCT04094038 studies End Stage Renal Disease, Malnutrition, Sarcopenia, Hemodialysis Complication.

What drugs are being tested in NCT04094038?

Interventions: Olimel N12, Glucose IV.

What is the status of NCT04094038?

NCT04094038 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2026-02-10 · How we verify

The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients

NCT04094038 Phase 4 ACTIVE_NOT_RECRUITING

Protein-energy wasting (PEW), a hypercatabolic state characterized by loss of muscle mass and fuel reserves, is highly prevalent in hemodialysis patients. Nutritional status and body composition are closely linked to morbidity, mortality and quality of life. Lean tissue mass (LTM) appears to be the best read-out for the association between nutritional status and outcomes. Intradialytic parenteral nutrition (IDPN) is occasionally used with the aim to reduce loss of LTM, but its efficacy has not been established. The goal of this study is to study the effect of IDPN on changes in LTM in hemodialysis patients.

Details

Lead sponsor	Erasmus Medical Center
Phase	Phase 4
Status	ACTIVE_NOT_RECRUITING
Enrolment	166
Start date	2019-09-16
Completion	2026-07

Conditions

End Stage Renal Disease
Malnutrition
Sarcopenia
Hemodialysis Complication

Interventions

Olimel N12
Glucose IV

Primary outcomes

Change in lean tissue mass — 16 weeks
Measured by body composition monitor (BCM)

Countries

Netherlands